|
|
|
|
|
|||||||
|
Session 91
Poster Session
Cardiovascular Disease Risk 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 692-T. | Zidovudine (AZT) Increases Endothelial Superoxide Generation which Results in Abnormal Endothelium-Dependent Relaxation R. Sutliff*, S. Dikalov, R. Russ, and W. Lewis Emory Univ., Atlanta, GA
| ||
| 693-T. | Circulating Cell Adhesion Molecules Are Elevated in HIV+ Women L. Bausserman*, K. Tashima, M. Dispigno, and D. Maceroni Miriam Hosp., Brown Med. Sch., Providence, RI
| ||
| 694-T. | ACTG 5056: C-Reactive Protein (CRP) Levels and Cardiovascular Risk Status for a Cohort of HIV-1-Infected Persons Durably Suppressed on an Indinavir (IDV)-Containing Regimen K. Henry*1, R. Zackin2, M. Dube3, S. Hammer4, D. Sprecher5, and J. Currier6 for the ACTG 5056/372A Team 1Univ. of Minnesota, Minneapolis; 2Harvard Univ., Boston, MA; 3Indiana Univ., Indianapolis; 4Columbia Univ., New York, NY; 5Cleveland Clin., OH; and 6Univ. of California, Los Angeles
| ||
| 695-T. | The Risk of Ischemic Cardiovascular Disease Is Significant in Persons with HIV Infection J. L. Wall*, M. David, and C. J. Fichtenbaum Univ. of Cincinnati Coll. of Med., OH
| ||
| 696-T. | Hospitalizations for Coronary Heart Disease and Myocardial Infarction among HIV+ Patients in the HAART Era D. Klein*,, and L. Hurley Kaiser Permanente Med. Care Program, Oakland, CA
| ||
| 697-T. | Coronary Heart Disease Risk (CHD) in French HIV-Infected Men Started on a Protease Inhibitor (PI)-Containing Regimen Compared to the General Population C. Leport1*, M. Saves2, P. Ducimetiere3, G. Le Moal4, P. Amouyel5, D. Arveiler6, J. Ferrieres7, J. Reynes8, S. Duran9, G. Chêne2 for the French WHO MONICA Project, and APROCO (ANRS EP11) Study Group 1Hosp. Bichat, Paris; 2INSERM U330, Bordeaux; 3INSERM U258, Villejuif; 4CHU, Poitiers; 5INSERM U508, Lille; 6Dept. d’Epidémiologie et Santé Publique, Strasbourg; 7INSERM U558, Toulouse; 8Hosp. Gui de Chauliac, Montpellier; and 9INSERM U379, Marseille, France
| ||
| 698-T. | Protease Inhibitor Use and Adverse Cardiovascular Outcomes in Ambulatory HIV Patients S. Holmberg*1, A. Moorman1, T. Tong1, D. Ward2, K. Wood3, A. E. Greenberg1, and R. S. Janssen1 for the HIV Outpatient Study (HOPS) Investigators4 1CDC, Atlanta, GA; 2Dupont Circle Physicians Group, Washington, DC; 3Cerner Corp., Vienna, VA; and 48 U.S. cities
|
